Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

RegulatoryRYBREVANT FASPROPositive

AI Analysis

Summary

Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) received FDA Priority Review designation as a potential first-in-class subcutaneous dual EGFR and MET-targeted treatment for recurrent or metastatic head and neck cancer, with clinical data showing a 42% overall response rate.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Priority Review designation granted by FDA

Importance:7/10

Sentiment:

0.85

FDA Priority Reviewsubcutaneous treatmentEGFR-MET targetedhead and neck cancerfirst-in-class potential42% ORR

Related Companies

$JNJ

Read the original article

Published by PR Newswire Biotech on July 30, 2026 12:30 PM

Read Original

Johnson &amp; Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Summary

Clinical Trial Data

Outcome Details

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer